Narcolepsy

The FDA has approved Lumryz, an extended-release formulation of sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.

Treatment with pitolisant demonstrated significant efficacy in reducing excessive daytime sleepiness and cataplexy in children aged 6 years and older, according to research presented in The Lancet Neurology.

Excessive daytime sleepiness is a common symptom of several sleep disorders, including obstructive sleep apnea, which is estimated to affect 10% to 30% of adults in the U.S and often goes underdiagnosed, according to the Sleep Foundation.

In this edition, we bring you news and Healio-exclusive interviews from the American Neurological Association Annual Meeting.

CHICAGO — Pain, sleep and mood disorders were the most commonly found comorbidities among those with narcolepsy, with chronic pain being more than twice as likely to occur compared with matched controls, a poster showed at ANA 2022.

The FDA has granted tentative approval to Lumryz, a once-at-bedtime oral treatment for excessive daytime sleepiness or cataplexy in adults with narcolepsy, Avadel Pharmaceuticals announced in a press release.

Jazz Pharmaceuticals announced it has entered into a licensing agreement with Sumitomo Pharma Co. to develop and commercialize an oral treatment for narcolepsy, idiopathic hypersomnia and other sleep disorders.

The FDA granted orphan drug exclusivity for JZP258, an oral low-sodium oxybate solution for the treatment of idiopathic hypersomnia in adults, according to Jazz Pharmaceuticals.

A 14-item self-reported scale improved the management of and provided guidance for narcolepsy type 1 among children and adolescents aged 10 to 18 years, according to study findings published in Neurology.